Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Equity

v3.22.1
Condensed Consolidated Statements of Equity - USD ($)
shares in Thousands, $ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Total
Balance at Jun. 30, 2020   $ 140 $ 206,931 $ (33) $ (150,420) $ (11) $ 56,607
Balance (in shares) at Jun. 30, 2020 6 140,071          
Capital raises   $ 11 32,111       32,122
Capital raises (in shares)   11,292          
Costs to raise capital     (1,525)       (1,525)
Exercise of stock options     28       28
Exercise of stock options (in shares)   30          
Conversion of preferred stock to common stock   $ 29 (29)        
Conversion of preferred stock to common stock (in shares) (6) 28,925          
Share-based compensation     351       351
Unrealized loss on debt securities       (7)     (7)
Net loss         (7,533) (1) (7,534)
Balance at Sep. 30, 2020   $ 180 237,867 (40) (157,953) (12) 80,042
Balance (in shares) at Sep. 30, 2020   180,318          
Balance at Jun. 30, 2020   $ 140 206,931 (33) (150,420) (11) 56,607
Balance (in shares) at Jun. 30, 2020 6 140,071          
Unrealized loss on debt securities             (36)
Net loss             (23,327)
Balance at Mar. 31, 2021   $ 216 278,442 (70) (173,743) (15) 104,830
Balance (in shares) at Mar. 31, 2021   216,133          
Balance at Sep. 30, 2020   $ 180 237,867 (40) (157,953) (12) 80,042
Balance (in shares) at Sep. 30, 2020   180,318          
Capital raises   $ 32 38,243       38,275
Capital raises (in shares)   31,451          
Costs to raise capital     (3,117)       (3,117)
Share-based compensation     265       265
Unrealized loss on debt securities       (13)     (13)
Net loss         (8,129) (2) (8,131)
Balance at Dec. 31, 2020   $ 212 273,258 (53) (166,082) (14) 107,321
Balance (in shares) at Dec. 31, 2020   211,769          
Capital raises   $ 4 4,880       4,884
Capital raises (in shares)   4,354          
Costs to raise capital     (71)       (71)
Costs to raise capital (in shares)   10          
Exercise of stock options     1       1
Share-based compensation     374       374
Foreign currency translation adjustment       (1)     (1)
Unrealized loss on debt securities       (16)     (16)
Net loss         (7,661) (1) (7,662)
Balance at Mar. 31, 2021   $ 216 278,442 (70) (173,743) (15) 104,830
Balance (in shares) at Mar. 31, 2021   216,133          
Balance at Jun. 30, 2021   $ 217 282,058 (63) (173,627) (17) 108,568
Balance (in shares) at Jun. 30, 2021   217,873          
Exercise of stock options     77       77
Exercise of stock options (in shares)   85          
Share-based compensation     821       821
Unrealized loss on debt securities       (1)     (1)
Net loss         (8,939) (1) (8,940)
Balance at Sep. 30, 2021   $ 217 282,956 (64) (182,566) (18) 100,525
Balance (in shares) at Sep. 30, 2021   217,958          
Balance at Jun. 30, 2021   $ 217 282,058 (63) (173,627) (17) 108,568
Balance (in shares) at Jun. 30, 2021   217,873          
Unrealized loss on debt securities             (131)
Net loss             (33,250)
Balance at Mar. 31, 2022   $ 218 286,232 (194) (206,876)   79,380
Balance (in shares) at Mar. 31, 2022   218,166          
Balance at Sep. 30, 2021   $ 217 282,956 (64) (182,566) (18) 100,525
Balance (in shares) at Sep. 30, 2021   217,958          
Vesting of RSU's   $ 1 (1)        
Vesting of RSU's (in shares)   103          
Warrant issued for Transaction     967       967
Acquisition of remaining portion of iBio CDMO     (68)     $ 18 (50)
Share-based compensation     1,103       1,103
Unrealized loss on debt securities       (27)     (27)
Net loss         (11,920)   (11,920)
Balance at Dec. 31, 2021   $ 218 284,957 (91) (194,486)   90,598
Balance (in shares) at Dec. 31, 2021   218,061          
Vesting of RSU's     1       1
Vesting of RSU's (in shares)   105          
Share-based compensation     1,274       1,274
Unrealized loss on debt securities       (103)     (103)
Net loss         (12,390)   (12,390)
Balance at Mar. 31, 2022   $ 218 $ 286,232 $ (194) $ (206,876)   $ 79,380
Balance (in shares) at Mar. 31, 2022   218,166